Clinical Trial Update: A Study of Liposomal Trans Crocetin, LEAF-4L6715, in Patients With Acute Respiratory Distress Syndrome Due to COVID-19, Sepsis or Other Causes [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update on LEAF-4L6715 (liposomal trans-crocetin) for acute respiratory distress syndrome related to COVID-19, sepsis, or other causes; study sta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome

Drugs mentioned

• LEAF-4L6715

Snippet

Sponsor: Institut de cancérologie Strasbourg Europe | Conditions: COVID19, Sepsis or Other Causes, Acute Respiratory Distress Syndrome | Phase 1, Phase 2 | Status: COMPLETED